BioNTech SE (BNTX)
After hours:
| Previous close | 92.72 |
| Open | 90.09 |
| Bid | 93.27 x 100 |
| Ask | 93.58 x 100 |
| Day's range | 90.00 - 95.29 |
| 52-week range | 85.21 - 125.83 |
| Volume | |
| Avg. volume | 598,828 |
| Market cap | 22.496B |
| Beta (5Y monthly) | 0.23 |
| PE ratio (TTM) | 22.71 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 02 June 2022 |
| 1y target est | N/A |
- Investor's Business Daily
BioNTech Lifts As Covid Sales Plummet With 90% Of Revenue Still To Come
BioNTech stock lifted a fraction Monday after Covid vaccine sales dropped again in the first quarter, amid wide losses.
- Barrons.com
BioNTech Revenue Falls Sharply on Reduced Covid Vaccine Sales
The pharmaceutical company posts a first-quarter loss of €1.31 a share, a swing from year-earlier profit of €2.05.
- Reuters
UPDATE 1-BioNTech says 90% of 2024 revenues will accrue at end of year
Germany's BioNTech , whose COVID-19 vaccine in partnership with Pfizer was widely used during the pandemic, said on Monday that almost all of its expected 2024 revenues would come in at the end of the year. BioNTech, which is investing money earned during the pandemic in cancer drug development, said in a statement that it is still targeting 2024 revenues in a range of 2.5 billion euros ($2.69 billion) to 3.1 billion euros. "BioNTech expects to recognize approximately 90% of its full year revenues in the last months of 2024," the company added.
